NIDEK announces CE mark for IOL injector, launch of new OCT device


The NP-1/NP-1C preloaded IOL injector has already been made available in parts of Asia

The NP-1/NP-1C, left, and RS-1 Glauvas Optical Coherence Tomography device, right. Images courtesy NIDEK Co., LTD.

The NP-1/NP-1C, left, and RS-1 Glauvas Optical Coherence Tomography device, right. Images courtesy NIDEK Co., LTD.

NIDEK Co., LTD., shared news about two products in its ophthalmic technology portfolio. The company received a CE mark for its NP-1/NP-1C injector, which is preloaded with the Aktis SP IOL.1 The injector is already available in Japan, where NIDEK is headquartered, and other parts of Asia. The CE mark approval will extend its availability throughout Europe. NIDEK described the NexLoad NP (NP-1), a tinted model, and the NexLoad NP Clear (NP-1C), as a “fully preloaded injection system with an aspheric hydrophobic soft acrylic lens.” The injector boasts a dual silicone ring on the plunger, for added stability. The lens itself has unique haptic design to increase stability and contact area for the capsular bag.1 The NP-1/NP-1C is available in a wide range of powers from 1.0 to 30.0 D.

“Surgeon feedback has been very positive, especially on the smooth IOL insertion and the availability of the expanded range of IOL power with the same delivery system,” said NIDEK CEO and President Motoki Ozawa, in a press release.1

Additionally, NIDEK launched its RS-1 Glauvas Optical Coherence Tomography (OCT) device, which has up to 250kHz scan speed and comes equipped with deep learning (DL)-based analytics.2 According to a press release, the advanced analytics for glaucoma and retinal diseases include a long axial length normative database and scan width correction. Meanwhile, DL-enhanced segmentation helps practitioners construct a Structural Normality Map (SN Map), which presents structural abnormalities and early signs of retinal change. The SN Map was developed in conjunction with Kagoshima University.

High-speed imaging reduces capture time; the RS-1 incorporates 250,000 A-scans, which puts ease of use and patient comfort at the forefront. A single B-scan image presents the area from the optic nerve head to the temporal vascular arcade, with a 4.2 mm depth. In addition, NIDEK noted that improvements to the AngioScan OCT-Angiography provide clearer images of the chorioretinal microvasculature.2 “The engineering and technical advances incorporated into the RS-1 Glauvas help address physician and staff workload by achieving high-speed imaging and excellent operability,” Ozawa stated.2 “In addition, our innovative analytics functions will enhance clinical efficiency and diagnostic confidence.”


1. NIDEK Co., LTD. NIDEK receives CE mark approval for the new preloaded IOL injection system. News release. Published 10 June, 2024. Accessed 12 June, 2024.
2. NIDEK Co., LTD. NIDEK launches the RS-1 Glauvas Optical Coherence Tomography. News release. Published 3 June, 2024. Accessed 12 June, 2024.
Recent Videos
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
© 2024 MJH Life Sciences

All rights reserved.